The Wayback Machine - https://web.archive.org/web/20251104062129/https://www.wsgr.com/en/insights/index.html
WSGR logoWSGR logo
Insights
Type
People
Practices
Industries
White Papers/Briefs
Navigating Shareholder Engagement and Shareholder Activism: Essentials and Best Practices
Discover essential insights and best practices for navigating shareholder engagement and activism by reading our latest white paper.
Read More
Newsletters
2025 Mid-Year Technology and Life Sciences PIPE and RDO Report
Dive into our mid-year review of 68 PIPEs and RDOs by U.S. technology and life sciences firms between January 1 and June 30, 2025. Key findings include a decline in life sciences activity and robust strength in the technology sector.
Read More
Newsletters
All Eyes on AI: Regulatory, Litigation, and Transactional Developments - Q2 2025

The latest edition of All Eyes on AI addresses the White House’s AI Action Plan, the USPTO’s plan to accelerate patent review, the EC’s details of the EU AI Act for GPAI requirements, and the Japanese market’s study on generative AI markets.

Read More

All Results

News Articles

11.03.25

Maureen Ohlhausen Inducted to ABA Antitrust Law Section’s Hall of Fame-inism
The American Bar Association’s Antitrust Law Section has named Wilson Sonsini antitrust partner Maureen Ohlhausen among the four inductees to its “Hall of Fame-inism.” The 2025 inductees have made significant contributions to supporting and promoting women in the antitrust, consumer protection, and data privacy fields through mentoring, sponsoring, hiring, creating leadership opportunities, and more.
Client Highlights

11.03.25

Wilson Sonsini Advises Pear Suite on $7.6 Million Series A Funding
On October 14, 2025, Pear Suite, a digital health company empowering community health workers, announced that it has raised $7.6 million in Series A funding. The investment round is led by Rock Health Capital and Nexxus Holdings, with support from Mucker Capital, Enable Ventures, The SCAN Foundation, Acumen America, Impact Engine, and the California Health Care Foundation. Wilson Sonsini Goodrich & Rosati advised Pear Suite on the transaction.
News Articles

10.31.25

Caz Hashemi Named Among Securities Docket's 2025 Enforcement Elite
On October 30, 2025, Securities Docket named Wilson Sonsini litigation partner Caz Hashemi to its Enforcement Elite, an elite list of the best securities enforcement defense lawyers in the industry. The honorees hail from the top law firms in the world and have been key players in some of the most significant SEC enforcement matters over the past few decades.
Client Highlights

10.31.25

Firm Advises Curve Biosciences on $40 Million Funding
On October 29, 2025, Curve Biosciences, the Whole-Body Intelligence™ company, announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others. The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring.

Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Alerts

10.30.25

SEC Chairman Addresses Potential Reforms Relating to Shareholder Proposals and Shareholder Litigation
On October 9, 2025, Chairman Paul S. Atkins of the U.S. Securities and Exchange Commission (SEC) gave a much-publicized keynote address at the University of Delaware’s John L. Weinberg Center for Corporate Governance.1 In the speech, Chairman Atkins generally expressed concern over the costs and difficulties facing public companies in the U.S. and identified several possible areas of reform, including with respect to practices surrounding shareholder proposals at shareholder meetings and the current shareholder litigation environment. These remarks follow a Policy Statement issued by the SEC on September 17, 2025, signaling that the use of mandatory arbitration provisions in a company’s governing documents to address shareholder litigation would not impact the SEC’s decisions to declare registration statements effective.2 Public companies, and those companies considering going public, will want to monitor these developments closely.
Alerts

10.30.25

Treasury Secretary Bessent Announces Suspension of 50 Percent “Affiliate” Rule for Entity List, Military End-Users List
During a televised interview today, Treasury Secretary Scott Bessent announced that the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) will suspend implementation of the so-called “Affiliates Rule,” which was adopted by BIS as an interim final rule last month. Under this new Affiliates Rule, BIS expanded the scope of the Entity List, Military End User (MEU) List, and Section 744.8 restrictions to also apply to non-U.S. entities owned, directly or indirectly, and individually or in the aggregate, 50 percent or more by another party or parties enumerated on an applicable list.
News Articles

10.30.25

Wilson Sonsini Lawyers Matt Christiansen and Nic Gladd Quoted by New Project Media on Department of Energy Grid Directive
Energy Secretary Chris Wright’s recent order instructs the Federal Energy Regulatory Commission (FERC) to assert federal jurisdiction over certain large-load interconnections to the power grid in an effort to expedite the interconnection of data centers.
White Papers/Briefs

10.29.25

Navigating Shareholder Engagement and Shareholder Activism: Essentials and Best Practices
Discover essential insights and best practices for navigating shareholder engagement and activism by reading our latest white paper.
Client Highlights

10.28.25

Wilson Sonsini Advises Avidity Biosciences on IP Matters Related to $12 Billion Acquisition by Novartis
On October 26, 2025, Novartis announced that it has entered into an agreement to acquire Avidity Biosciences, a San Diego-based biopharmaceutical company focused on a new class of therapeutics enabling RNA delivery to muscle. The acquisition will follow the separation of Avidity’s early-stage precision cardiology programs. Wilson Sonsini Goodrich & Rosati advised Avidity Biosciences on patent matters related to the transaction.
Client Highlights

10.28.25

Wilson Sonsini Advises Centerview as Financial Advisor to Qorvo in Skyworks Acquisition
On October 28, 2025, Skyworks, a global leader in high-performance analog and mixed-signal semiconductors, and Qorvo, a leading global provider of connectivity and power solutions, announced they have entered into a definitive agreement to combine the two companies in a cash-and-stock transaction to create a U.S.-based, global leader in high-performance radio frequency (RF), analog, and mixed-signal semiconductors. Under the terms of the agreement, Qorvo shareholders will receive $32.50 in cash and 0.960 of a Skyworks common share for each Qorvo share held at the close of the transaction, which implies a combined enterprise value of approximately $22 billion. Wilson Sonsini Goodrich & Rosati advised Centerview Partners LLC, the financial advisor to Qorvo, on the transaction.
Client Highlights

10.28.25

Wilson Sonsini Advises Empirico on License Agreement with GSK
On October 28, 2025, GSK and Empirico, a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide. EMP-012 addresses a novel therapeutic target and is currently in a Phase 1 trial for the treatment of chronic obstructive pulmonary disease (COPD), with the potential for expansion into other inflammatory respiratory diseases. Wilson Sonsini Goodrich & Rosati advised Empirico on the transaction.
Client Highlights

10.28.25

Wilson Sonsini Advises WuXi AppTec on Sale of China-Based Clinical Research Services Business to Hillhouse
On October 24, 2025, WuXi AppTec Co., Ltd. (WuXi AppTec), a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that its wholly owned subsidiary has entered into a sale and purchase agreement to sell its two subsidiaries, WuXi Clinical Development Services (Shanghai) Co., Ltd. (WuXi Clinical) and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. (WuXi MedKey), to Hillhouse Investment Management (Hillhouse), one of the world’s leading global private asset managers focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology. WuXi Clinical and WuXi MedKey are the operating entities of WuXi AppTec engaged in China-based clinical research services.

Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes:
WSGR logo
Copyright © 2025 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.